Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

T Cell Activation Bioassay (NFAT) Technical Manual

Instructions for Use of Product(s)
J1621, J1625, J1622, J1626

Literature # TM490

The T Cell Activation Bioassay (NFAT) is a bioluminescent cell-based assay that overcomes the limitations of existing assays and can be used for the discovery and development of novel biologic and cell therapies aimed at inducing, strengthening and/or engineering T cell responses. The assay consists of a genetically engineered Jurkat T cell line that expresses a luciferase reporter driven by an NFAT-response element (NFAT-RE). The TCR/CD3 Effector Cells (NFAT) are provided in Cell Propagation Model (CPM) format, which includes cryopreserved cells that can be thawed, propagated and banked for long-term use.

The TCR/CD3 Effector Cells express endogenous TCR, CD3 and CD28 receptors. When the TCR/CD3 Effector Cells (NFAT) are engaged with an appropriate TCR/CD3 ligand or anti-TCR/CD3 antibody, the TCR transduces intracellular signals resulting in NFAT-RE-mediated luminescence. The bioluminescent signal is detected and quantified using Bio-Glo™ Luciferase Assay System and a standard luminometer, such as the GloMax® Discover System.

This Technical Manual is relevant for Cat.# J1621 and J1625; J1622 and J1626 (Korea).

Summary of Changes
The following changes were made to the 1/24 revision of this document:
1. Updated patent statements.
2. Changed font and cover image.
3. Made minor text edits. 

Revised 1/24